As of March 26, we're $27,100 in the red for the quarter. Donate here to support this vital work
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Silicon Valley and Wall Street Elites Pour Money Into Psychedelic Research
Key Excerpts from Article on Website of Wall Street Journal


Wall Street Journal, August 20, 2020
Posted: September 7th, 2020
https://www.wsj.com/articles/silicon-valley-and-wall-street-...

A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy. The Multidisciplinary Association for Psychedelic Studies, a nonprofit advocating for psychedelic research since the 1980s, is conducting its last phase of clinical trials to research the efficacy of using MDMA-assisted psychotherapy for post-traumatic stress disorder. PTSD afflicts about eight million adults a year. MDMA is more commonly known as the main component of Ecstasy. Armed with the new funding, MAPS is aiming to finish the trials and seek approval from the Food and Drug Administration to commercialize the MDMA-assisted psychotherapy as soon as 2022. In 2017, the FDA designated MDMA as a breakthrough therapy for PTSD, meaning it would expedite review of the drug. MAPS said a recent interim analysis of its Phase 3 clinical trials ... showed a very high likelihood the therapy will be effective for treating PTSD. In phase 2 clinical trials, individuals with post-traumatic stress disorder received psychotherapy, some with the psychedelic drug MDMA. More of those who received the drug no longer received a PTSD diagnosis in the months after treatment, compared with those who received a placebo. Business leaders said their donations came from a personal connection to mental-health conditions. Among them is billionaire Bob Parsons, founder of GoDaddy and ... a Marine Corps Vietnam War veteran, who said he has continued to battle PTSD.

Note: To read the entire article free of charge, see this webpage. Note that as big Pharma won't make big profits from these therapies, they are not funding any of the major studies, while the nonprofit MAPS has stepped in to make this happen. And not mentioned in this article is that the results of these studies has been dramatic, with over 2/3 of patients showing no signs of PTSD a year after treatment. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.


Latest News


Key News Articles from Years Past